Back to Screener

Revolution Medicines, Inc. Warrant (RVMDW)

Price$5.43

Favorite Metrics

Price vs S&P 500 (26W)1470.64%
Price vs S&P 500 (4W)185.19%

All Metrics

Price vs S&P 500 (YTD)483.34%
10-Day Avg Trading Volume0.53M
3-Month Avg Trading Volume0.13M
52-Week High$6.22
26-Week Price Return1475.19%
13-Week Price Return72.19%
3-Month Return Std Dev287.86%
Year-to-Date Return486.23%
5-Day Price Return188.48%
Month-to-Date Return207.82%
Price vs S&P 500 (13W)71.05%
52-Week Low$0.04

Industry Peers — Biological Products(89)

SymbolP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
RVMDWRevolution Medicines, Inc. Warrant
$5.43
AMGNAmgen Inc
5.21x9.95%73.30%2.93%$355.30
GILDGilead Sciences Inc
5.80x2.40%78.83%133.64%$137.64
ARGXargenx SE American Depositary Shares
12.46x89.56%150.91%$849.04
BNTXBioNTech SE American Depositary Share
8.99x-11.81%84.21%$102.92
BIIBBiogen Inc. Common Stock
2.63x2.22%75.69%-18.77%$177.35
MRNAModerna, Inc. Common Stock
10.91x-39.93%70.32%$53.72
NBIXNeurocrine Biosciences Inc
4.68x21.45%98.18%2.31%$133.25
EXELExelixis Inc
5.02x6.85%96.39%31.10%$44.89
TECHBio-Techne Corp.
7.62x1.64%66.60%-20.58%$59.23
HALOHalozyme Therapeutics, Inc.
5.88x37.55%83.62%22.89%$69.29

About

Revolution Medicines is a clinical-stage precision oncology company developing targeted therapies for RAS-addicted cancers, a significant unmet need in oncology. Using proprietary structure-based drug discovery, the company creates small molecules that target unconventional binding sites on RAS variants. Its pipeline features RAS(ON) Inhibitors designed as monotherapy or combination treatments.